Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131I or 111In: An intrapatient comparison

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  Brouwers, Adrienne H ^a   Buijs, Wilhelmina C A M ^a   Oosterwijk, Egbert ^a   Boerman, Otto C ^a   Mala, Carola ^b   De Mulder, Pieter H M ^a   Corstens, Frans H M ^a   Mulders, Peter F A ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Wilex Biotechnology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INDIUM 111; IODINE 131; ISOTHIOCYANATOBENZYL DIETHYLENETRIAMINEPENTAACETIC ACID; ISOTHIOCYANIC ACID DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; PENTETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY LABELING; ANTIGEN EXPRESSION; CALCULATION; CELLULAR DISTRIBUTION; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG RETENTION; FEMALE; FUTUROLOGY; HALF LIFE TIME; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; ISOTOPE LABELING; KIDNEY CARCINOMA; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; RANDOMIZED CONTROLLED TRIAL; SCINTILLATION CAMERA; TARGET ORGAN; TUMOR BLOOD FLOW;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUALITY CONTROL; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0141568092     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Liu, S. Y., Eary, J. F., Petersdorf, S. H., Martin, P. J., Maloney, D. G., Appelbaum, F. R., Matthews, D. C., Bush, S. A., Durack, L. D., Fisher, D. R., Gooley, T. A., Bernstein, I. D., and Press, O. W. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol., 16: 3270-3278, 1998.
2. 131I-labelled monoclonal antibody E48 IgG. Br. J. Cancer, 66: 496-502, 1992.
3. Behr, T. M., Liersch, T., Greiner-Bechert, L., Griesinger, F., Behe, M., Markus, P. M., Gratz, S., Angerstein, C., Brittinger, G., Becker, H., Goldenberg, D. M., and Becker, W. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (Phila), 35: 1373-1381, 2002.
4. Shih, L. B., Thorpe, S. R., Griffiths, G. L., Diril, H., Ong, G. L., Hansen, H. J., Goldenberg, D. M., and Mattes, M. J. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J. Nucl. Med., 35: 899-908, 1994.
5. Geissler, F., Anderson, S. K., Venkatesan, P., and Press, O. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res., 52: 2907-2915, 1992.
6. Press, O. W., Shan, D., Howell-Clark, J., Eary, J., Appelbaum, F. R., Matthews, D., King, D. J., Haines, A. M., Hamann, P., Hinman, L., Shochat, D., and Bernstein, I. D. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res., 56: 2123-2129, 1996.
7. Sharkey, R. M., Behr, T. M., Mattes, M. J., Stein, R., Griffiths, G. L., Shih, L. B., Hansen, H. J., Blumenthal, R. D., Dunn, R. M., Juweid, M. E., and Goldenberg, D. M. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol. Immunother., 44: 179-188, 1997.
8. Oosterwijk, E., Bander, N. H., Divgi, C. R., Welt, S., Wakka, J. C., Finn, R. D., Carswell, E. A., Larson, S. M., Warnaar, S. O., Fleuren, G. J., Oettgen, H. F., and Old, L. J. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol., 11: 738-750, 1993.
9. Steffens, M. G., Boerman, O. C., Oosterwijk-Wakka, J. C., Oosterhof, G. O., Witjes, J. A., Koenders, E. B., Oyen, W. J., Buijs, W. C., Debruyne, F. M., Corstens, F. H., and Oosterwijk, E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol., 15: 1529-1537, 1997.
10. Divgi, C. R., Bander, N. H., Scott, A. M., O'Donoghue, J. A., Sgouros, G., Welt, S., Finn, R. D., Morrissey, F., Capitelli, P., Williams, J. M., Deland, D., Nakhre, A., Oosterwijk, E., Gulec, S., Graham, M. C., Larson, S. M., and Old, L. J. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res., 4: 2729-2739, 1998.
11. 131I-labeled chimeric monoclonal antibody G250. Clin. Cancer Res., 5: 3268s-3274s, 1999.
12. Kranenborg, M. H., Boerman, O. C., De Weijert, M. C., Oosterwijk-Wakka, J. C., Corstens, F. H., and Oosterwijk, E. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer (Phila.), 80: 2390-2397, 1997.
13. Boerman, O. C., Kranenborg, M. H., Oosterwijk, E., Griffiths, G. L., McBride, W. J., Oyen, W. J., De Weijert, M., Oosterwijk-Wakka, J., Hansen, H. J., and Corstens, F. H. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res., 59: 4400-4405, 1999.
14. Dürrbach, A., Angevin, E., Poncet, P., Rouleau, M., Chavanel, G., Chapel, A., Thierry, D., Gorter, A., Hirsch, R., Charpentier, B., Senik, A., and Hirsch, F. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther., 6: 564-571, 1999.
15. Stein, R., Chen, S., Haim, S., and Goldenberg, D. M. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer (Phila.), 80: 2636-2641, 1997.
16. 90Y labeled MAbs. Cancer Biother. Radiopharm., 14: 37-47, 1999.
17. Wiseman, G. A., Leigh, B., Erwin, W. D., Lamonica, D., Kornmehl, E., Spies, S. M., Silverman, D. H., Witzig, T. E., Sparks, R. B., and White, C. A. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer (Phila.), 94: 1349-1357, 2002.
18. O'Donnell, R. T., DeNardo, S. J., Yuan, A., Shen, S., Richman, C. M., Lara, P. N., Griffith, I. J., Goldstein, D. S., Kukis, D. L., Martinez, G. S., Mirick, G. R., DeNardo, G. L., and Meyers, F. J. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res., 7: 1561-1568, 2001.
19. Johnson, T. K., Cole, W., Quaife, R. A., Lear, J. L., Ceriani, R. L., Jones, R. B., and Cagnoni, P. J. Biokinetics of yttrium-90-labeled huBrE-3 monoclonal antibody. Cancer (Phila.), 94: 1240-1248, 2002.
20. Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., and Warnaar, S. O. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer, 38: 489-494, 1986.
21. Velders, M. P., Litvinov, S. V., Warnaar, S. O., Gorter, A., Fleuren, G. J., Zurawski, V. R., Jr., and Coney, L. R. New chimeric antipancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res., 54: 1753-1759, 1994.
22. Pastorekova, S., Parkkila, S., Parkkila, A. K., Opavsky, R., Zelnik, V., Saarnio, J., and Pastorek, J. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology, 112: 398-408, 1997.
23. Uemura, H., Nakagawa, Y., Yoshida, K., Saga, S., Yoshikawa, K., Hirao, Y., and Oosterwijk, E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer, 81: 741-746, 1999.
24. Kaluz, S., Kaluzova, M., Opavsky, R., Pastorekova, S., Gibadulinova, A., Dequiedt, F., Kettmann, R., and Pastorek, J. Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase 1X. Identification and characterization of a proximal silencer element. J. Biol. Chem., 274: 32588-32595, 1999.
25. Grabmaier, K., Vissers, J. L., De Weijert, M. C., Oosterwijk-Wakka, J. C., Van Bokhoven, A., Brakenhoff, R. H., Noessner, E., Mulders, P. A., Merkx, G., Figdor, C. G., Adema, G. J., and Oosterwijk, E. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer, 85: 865-870, 2000.
26. Ruegg, C. L., Anderson-Berg, W. T., Brechbiel, M. W., Mirzadeh, S., Gansow, O. A., and Strand, M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res., 50: 4221-4226, 1990.
27. Hnatowich, D. J., Childs, R. L., Lanteigne, D., and Najafi, A. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J. Immunol. Methods, 65: 147-157, 1983.
28. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
29. Buijs, W. C., Massuger, L. F., Claessens, R. A., Kenemans, P., and Corstens, F. H. Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer. J. Nucl. Med., 33: 1113-1120, 1992.
30. Buijs, W. C., Siegel, J. A., Boerman, O. C., and Corstens, F. H. Absolute organ activity estimated by five different methods of background correction. J. Nucl. Med., 39: 2167-2172, 1998.
31. Perkins, A. C., and Pimm, M. V. Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. I. The effect on image contrast in clinical studies. Eur. J. Nucl. Med., 11: 295-299, 1985.
32. Carrasquillo, J. A., Mulshine, J. L., Bunn, P. A., Jr., Reynolds, J. C., Foon, K. A., Schroff, R. W., Perentesis, P., Steis, R. G., Keenan, A. M., and Horowitz, M. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J. Nucl. Med., 28: 281-287, 1987.
33. Yokoyama, K., Carrasquillo, J. A., Chang, A. E., Colcher, D., Roselli, M., Sugarbaker, P., Sindelar, W., Reynolds, J. C., Perentesis, P., and Gansow, O. A. Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J. Nucl. Med., 30: 320-327, 1989.
34. Steffens, M. G., Boerman, O. C., Oyen, W. J., Kniest, P. H., Witjes, J. A., Oosterhof, G. O., Van Leenders, G. J., Debruyne, F. M., Corstens, F. H., and Oosterwijk, E. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res., 59: 1615-1619, 1999.
35. Mattes, M. J., and Michel, R. B. Processing of antibody 1F5 (anti-CD20) bound to B-cell lymphomas. Cancer Biother. Radiopharm., 17: 474, 2002.
36. 131I-cG250 monoclonal antibody immunoscimigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl. Med. Commun., 23: 229-236, 2002.